MDM2 antagonists have been combined with other agents in different cancer types, such as with PI3K, MEK, or FLT3-ITD pathway inhibition in AML, with CD20 antibody in lymphoma, with CDK4/6 inhibitor in locally advanced or metastatic liposarcoma, with PD-L1/PD-1 antibodies in patients with metastatic solid tumors, and a number of others [73]. This evidence concerns the gene FLT3 and acute myeloid leukemia.